e-ISSN 2598-3849       print ISSN 2527-8878

Vol 2, No 2 (2017)

Cost of Treatment Demam Berdarah Dengue (DBD) di Rawat Inap Berdasarkan Clinical Pathway di RS X Jakarta

Vera Marietha Meinar Rejeki, Atik Nurwahyuni

Abstract


Abstrak

Rumah Sakit sebagai pemberi layanan kesehatan saat ini dituntut untuk melakukan kendali mutu dan biaya, namun tetap berkualitas. Clinical pathway yang menjadi dasar pengendalian mutu dan biaya sudah ada tetapi belum diaudit penggunaan­nya oleh tim rumah sakit. Penelitian ini bertujuan untuk mengetahui unit cost layanan dan cost of treatment DBD di RS X Ja­karta. Penelitian kuantitatif melalui pengambilan data cross sectional dengan jumlah sampel penelitian sebanyak 190 pasien DBD. Hasil penelitian didapatkan adanya kesenjangan antara cost of treatment perawatan pasien DBD berdasarkan clinical pathway (Rp. 2.184.588) dan cost of treatment berdasarkan kondisi riil (Rp. 2.382.512) dengan selisih terbesar di rawat inap dan obat-obatan. Cost of treatment tanpa perhitungan gaji dan investasi untuk pasien DBD dapat berkurang menjadi 29% dari cost of treatment semula. Cost of Treatment tanpa perhitungan gaji maka cost of treatment dapat turun menjadi 42%. Diperlukan sistem pemantauan kepatuhan terhadap clinical pathway, pembentukan tim casemix rumah sakit untuk peman­tauan dan evaluasi implementasi JKN di rumah sakit .

Abstract

Hospitals as health care providers are now required to perform cost and quality control without neglecting the quality of services. Clinical pathways which underlying quality and cost control in the hospital are available but has not been audited. This study aims to determine the unit cost of services in RS X Jakarta, the utilization of hospital services for dengue disease and cost of treatment of DHF in RS X Jakarta. A cross-sectional study was performed in this study. A quantitative approach was done through data collection from hospital information system, medical record and financial data. The result showed that there was a gap between the cost of treat­ment of DHF patients which based on the clinical pathway (2,184,588 IDR) and the cost of treatment based on the real condition (2,382,512 IDR). The biggest difference between cost of treatment and real cost was in the hospitalization cost and medicine cost. Cost of treatment without salary and investation calculation for DHF patients can be reduced significantly by 29%. Cost of treatment without salary calculation for DHF patients can be reduced significantly by 42%. There is a need for monitoring system and the estab­lishment of hospital case mix team in order to optimize the hospital clinical pathway in the JKN era.

 


Keywords


clinical pathway; cost of treatment; dengue hemorrhagic fever; unit cost

References


(1) Kementerian Kesehatan RI. 2016. Infodatin Situasi DBD. Jakarta: Pusat data dan informasi Kemen¬kes RI.

(2) Kementerian Kesehatan Republik Indonesia. 2013. Pedoman Pengendalian Demam Berdarah Den¬gue di Indonesia. Direktorat Jenderal Pengenda¬lian Penyakit dan Penyehatan Lingkungan.

(3) Kementerian Kesehatan Republik Indonesia. 2014. Pedoman Penyusunan Standar Pelayanan Ke¬dokteran. Konsorsium Upaya Kesehatan Direk¬torat Jendral Bina Upaya Kesehatan.

(4) Laporan Tahunan RS X Jakarta tahun 2016

(5) Perwira, Ita, 2011. Faktor – Faktor Yang Mempen¬garuhi Lama RI Pada Pasien Yang Terinfeksi Vi¬rus Dengue Di RSUP Persahabatan Jakarta Timur. Depok. Universitas Indonesia

(6) Primasari, R. 2015. Analisis Lama Hari Rawat pada Pasien BPJS dengan Kasus Demam Berdarah Den¬gue di Instalasi Rawat Inap RSUP Fatmawati peri¬ode Januari-Agustus tahun 2015. Depok. Universi¬tas Indonesia

(7) Pritts T, Nussbaum M, Flesch L, et.al. 1999. Imple¬mentation of a Clinical Pathway Decreases Length of Stay and Cost for Bowel Resection. Annals of Sur¬gery. Nov; 230(5): 728. Diakses dari https://www. ncbi.nlm.nih.gov/pmc/articles/PMC1420929/ tanggal 10 April 2018.

(8) Sulastomo. 1997. Asuransi Kesehatan dan Managed Care, PT. Asuransi Kesehatan Indonesia. Jakarta

(9) Sunarto E, Dewi A. 2016. Membangun Tata Kelola Klinis Melalui Clinical Pathway Demam Berdarah Dengue RSU Rizki Amalia Medika. Jurnal Medico¬eticoilegal dan Manajemen Rumah Sakit, Vol. 5 No. 2 Juli 2016.

(10) Sylvester AM, George M. 2014. Effect of a clinical pathway on length of stay and cost of pediatric inpa¬tient asthma admissions: an integrative review. Clin Nurs Res 2014 Aug;23(4):384-401. Diakses dari https://www.ncbi.nlm.nih.gov/pubmed/23676186 tanggal 10 April 2018.

(11) Tobing, R. 2013. Analisis Klaim Biaya Rawat Inap Kasus DBD Pasien JPK Gakin dan SKTM di Lima RSUD Provinsi DKI Jakarta Tahun 2011.

(12) Widjaja, B. 2009. Analisa Implementasi Integrated Care Pathway Kasus DBD di Ruangan Rawat Inap Kelas III RSUD Cengkareng tahun 2009. Depok, Universitas Indonesia

(13) Zailani, M. 2003. Jasa Medis di Rumah Sakit, Hopital Management Refresing Course and Exibition, Per¬mapkin, Jakarta.

(14) Zhang F, Kramer CV. 2014. Corticosteroid for treat¬ing dengue infection in children and adults. Diakses dari www.cochrane.org/CD003488/INFECTN_ corticosteroids-treating-dengue- infection-chil¬dren-and-adults tanggal 28 Mei 2017.

(15) Zhu L, Li J, Li XK, et.al. 2014. Impact of a Clini¬cal Pathway on Hospital Costs, Length of Stay and Early Outcomes after Hepatectomy for Hepatocel¬lular Carcinoma. Asian Pacific Journal of Cancer Prevention, Vol 15. Diakses dari https://pdfs.se-manticscholar.org/46d1/9451da7ccbf65a09a2c¬4b13c71f57008507e.pdf tanggal 10 April 2018.


Full Text: PDF

DOI: 10.7454/eki.v2i2.2146

Refbacks

  • There are currently no refbacks.